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ABSTRACT
Hexavalent chromium, or Cr(VI), is a potent oxidizer and known carcinogen that is 
found at varying levels in the water sources of more than 200 million Americans. 
However, the exact mechanism of carcinogenicity remains unknown, and though the 
government currently regulates total chromium levels they have yet to determine a 
permissible exposure limit for Cr(VI). Moreover, there is currently no preventative 
treatment for Cr(VI). Because of Cr(VI)’s strong oxidative power, we hypothesized 
that it causes DNA mutation and cell death via oxidation and that antioxidants could 
prevent this from occurring. To test this, we first assessed the viability of human cell 
culture exposed to Cr(VI) with or without either of the antioxidants vitamin C or 
epigallocatechin gallate (EGCG). Further, an Ames test was performed to determine 
the mutagenicity of Cr(VI) with and without either antioxidant.
We found that Cr(VI) is significantly toxic to cell culture at concentrations of 200 ppb 
(parts per billion) or more. Both vitamin C and EGCG blocked this effect at 10 ppm 
(parts per million) and 15 ppm, respectively, while neither antioxidant was observed to 
be cytotoxic when treated alone. Cr(VI) was also found to be significantly mutagenic 
at 20 ppb and greater. This mutagenicity was significantly reduced by cotreatment 
with 20 ppm vitamin C at 200 and 2000 ppb Cr(VI), while vitamin C was not found 
to be mutagenic when tested individually. With these combined data, we conclude that 
Cr(VI) is both cytotoxic and mutagenic via an oxidative mechanism and these effects 
can be abrogated by antioxidants. Though continued study is merited, this information 
further validates the protective potential of antioxidants against toxicants like Cr(VI).
Keywords: Hexavalent chromium, epigallocatechin gallate, ascorbic acid, 
cytotoxicity, mutagenicity, antioxidants.
INTRODUCTION
Hexavalent chromium
The toxicological effects of hexavalent chromium (Cr(VI)) compounds have been 
widely studied over the years. Specifically, data have been collected to assess its 
carcinogenic effects on humans through case study (Yu, 2013), and its toxicological 
effects on rats (Geetha et al., 2003) and cell cultures (Majone et al., 2002). Though 
there exist three different oxidative states for chromium, the hexavalent form has 
been found to be much more toxic than the quadrivalent form or the trivalent form, 
which is in fact an essential element for humans (Sun et al., 2015). Unfortunately, the 
toxicant can be found in hexavalent form in the tap water of nearly two-thirds of the 
United States’ drinking supply (Andrews & Walker, 2016). Though the environmental 
protection agency (EPA) monitors total chromium levels in drinking water, hexavalent 
levels are not monitored, and the toxicant is ingested daily. The EPA’s current maximum 
contaminant level for total chromium is 100 ppb, yet it is unclear if Cr(VI) at 100 
ppb could have detrimental effects on a population. In humans, hexavalent chromium 
toxicity through ingestion has been known to cause cardiovascular, gastrointestinal, 
hematological, hepatic, renal, and neurological damage, and in severe cases, causes 
cancer or death (Yu, 2013).
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Chromium is a naturally occurring element and often found at low levels in both 
the hexavalent and trivalent states in natural watersheds (Loyaux-Lawniczak et al., 
2001). However, chromium compounds are often used for chromium plating and other 
industrial uses and can elevate these low levels (Kamerud et al., 2013). Disposal of 
chromium containing commercial products and coal ash from electric utilities are 
major sources of chromium releases into the soil. Solid waste and slag produced during 
chromate manufacturing processes can be potential sources of chromium exposure as 
well (Barceloux 1999). Improper disposal and maintenance of Cr(VI) at these facilities 
can cause environmental contamination and drinking water pollution (Cone, 2009). A 
recent study done of Illinois water showed that hexavalent chromium concentrations 
were actually higher in treated water than those in untreated water. Indeed, Cr(VI) 
levels on surface water were found to be 0.3 ppb, and levels in bedrock aquifers at 
1.1 ppb, whereas those in treated water supplies were 2.4 ppb, indicating that water 
treatment practices may ironically play a role in increasing concentrations (Mills & 
Cobb, 2015). Though these levels are well below the EPA-regulated limit, it is still 
unknown whether these levels are detrimental to human health.
Mechanism of toxicity
The mechanism of toxicity of Cr(VI) has been found to be induction of oxidative stress, 
which further leads to cell toxicity and cell death (Bagchi et al., 2002; Chiu et al., 
2010). In their study, Martindale and Holbrook found that oxidative stress results when 
reactive oxygen species (ROS), either produced endogenously as a consequence of 
normal cellular functions or derived from external sources, cause damage that exceeds 
the cell’s ability to resist oxidation (Martindale & Holbrook, 2002). They went on 
to find that when ROS originate from exogenous sources, they are either taken up 
directly by cells from the extracellular matrix or produced as a consequence of the 
cell’s exposure to an environmental antagonist, such as Cr(VI). Transient fluctuations 
in ROS serve important regulatory functions such as in aerobic respiration, but when 
present in high levels, ROS can cause severe damage to DNA, protein, and lipids. A 
number of cellular defense mechanisms have evolved to combat the accumulation of 
ROS. These include various non-enzymatic molecules such as glutathione, and vitamins 
A, C, and E, as well as enzymatic scavengers of ROS like superoxide dismutase and 
catalase (Martindale & Holbrook, 2002). Unfortunately, these systems of defense are 
not always adequate to counteract the production of ROS, resulting in what is termed 
a state of oxidative stress. Because of its 6+ oxidation state, Cr(VI) is a potent oxidizer 
that can challenge the limited capacity of natural antioxidative systems.
Ames assay
Previous research shows that not only are hexavalent chromium compounds 
carcinogenic, but they are also directly mutagenic towards deoxyribonucleic acid 
(DNA) (Petrilli & Deflora, 1976). In this study, a genetically engineered strain of 
Salmonella typhimurium was exposed to differing solutions to test mutagenic potential. 
When exposed to a mutagen, this specific strain of bacteria will revert from a state 
of auxotrophy (inability to produce the essential amino acid histidine) to a state of 
prototrophy (ability to produce histidine). This genetic reversion allows the bacteria 
to survive and replicate, whereas a lack of mutation will result in death. Bacterial 
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survival, observed by colorimetric determination of its growth media, is therefore a 
direct indicator of DNA mutagenesis. This same study showed that the mutagenic 
effects were caused directly by Cr(VI) and not due to a metabolic byproduct within the 
bacteria (Petrilli & Deflora, 1976). This information therefore indicated that not only 
is Cr(VI) toxic to organisms but is also directly mutagenic toward cellular DNA, with 
a preventative treatment yet to be elucidated.
Reduction potential
Different approaches have been utilized to reduce the oxidizing potential of Cr(VI). For 
example, one study showed that the use of certain microorganisms as biological filters 
could be used to lower chromium levels (Thatoi et al., 2014), while several others have 
shown that antioxidants are effective (Chrysochoou & Reeves, 2016; Geetha et al., 
2003). Antioxidants lower the oxidation state of chromium from hexavalency to the 
lower, less harmful state of trivalency. One study showed that epigallocatechin gallate 
(EGCG) directly reduces Cr(VI) in solution (Chrysochoou & Reeves, 2013), whereas 
another showed that vitamin C also reduces Cr(VI) in solution and in the past has been 
used as a topical treatment against Cr(VI) skin exposure (Yu, 2013). A third study 
tested the effect of antioxidants extracted from the plant Hippophae rhamnoides on 
albino rats when co-fed with hexavalent chromium. Results suggested that rats that had 
been fed antioxidants along with the chromium compounds exhibited declines in tumor 
growth both in size and frequency compared to those without antioxidants (Geetha 
et al., 2003). Though this study demonstrates that a plant extract with antioxidant 
properties prevents Cr(VI)-induced toxicity at the organismal level, little is known 
about the effects of specific antioxidants at the cellular level. To date, there have been 
no studies of Cr(VI) and antioxidant cotreatment on human cell culture, and though 
antioxidants are known to reduce Cr(VI), there is still uncertainty in regard to which 
antioxidants are most effective. Additionally, the extent to which antioxidants are 
protective has yet to be elucidated; whether they protect against cytotoxicity upon 
the cell membrane and within the cytoplasm, or if they protect against mutagenesis 
within the nucleus as well. We hypothesized that when co-treated with an antioxidant, 
hexavalent chromium would exhibit less cytotoxicity on a human cell culture. We also 
hypothesized that when co-treated with an antioxidant, hexavalent chromium would 
exhibit less mutagenicity towards bacterial DNA.
METHODS
Cell culture, compounds, and storage
Human intestinal epithelial (HInEpi) cells were obtained from the American Type 
Culture Collection (ATCC) and were sustained on the cell line’s respective ATCC 
media. Human embryonic kidney (HEK) cells were obtained from a secondary passage 
in nitrogen storage in house at Reed Hall of Science, though the original passage was 
obtained from Dr. Seth Robia (Loyola University Chicago). These cells were sustained 
on Dulbecco’s Modified Eagle Medium with 10% Fetal Bovine Serum, 1% Penicillin-
Streptomycin, and 1% L-Glutamine, all of which were sourced from Sigma Aldrich. 
Cells were incubated at 37°C and 5% CO² and passaged once confluent using trypsin-
EDTA. Both L-ascorbic acid and epigallocatechin gallate were obtained from Sigma 
Aldrich. The Cr(VI) compound used for experimentation was potassium chromate, 
also obtained from Sigma Aldrich.
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Determination of treatment concentration
Experimental Cr(VI) concentrations were tested in magnitudes of ten ranging from 
2 ppb (parts per billion) to 20,000 ppb to simulate environmental conditions as well 
as coincide with previous literature. These concentrations were used for both cell 
proliferation and Ames procedures. Antioxidant concentrations were determined 
through experimentation, starting at a 1:1 ratio of antioxidant to Cr(VI) and adjusted 
accordingly based on response until effects were seen. 
Solution preparation
Stock solutions of Cr(VI), EGCG, and ascorbic acid were prepared by dissolving solute 
in double-distilled water at a concentration of 2000 ppm and then filter sterilizing. Once 
treatment concentrations had been determined as described above, smaller aliquots of 
stock solution were mixed with the appropriate cell media to bring the final mixture to 
the desired experimental concentration. Experimental solution containing both Cr(VI) 
and an antioxidant for cotreatment were prepared by bringing both a Cr(VI) solution 
and an antioxidant solution to twice their desired final concentration in media and 
then adding the two solutions together to dilute the sample down to its experimental 
concentration. Stock solutions were stored at 4°C and were remade several times 
throughout experimentation to avoid expiration. Experimental solutions were made 
within twenty-four hours of use.
Cellular proliferation assay
Both the HInEpi and HEK cells were passaged in T-75 flasks in respective media until 
confluency was reached. These cells were then passaged onto a 24-well plate and again 
cultured until wells reached confluence. Treatment groups were then run in quadruplicate, 
allowing for six sample groups per plate that were exposed to solution for 72 hours. To 
depict qualitative results, photos were taken of wells at points of interest along the way 
using a Nikon TXI inverted microscope with phase contrast.
After the 72-hour incubation period, media was aspirated and cells were trypsinized and 
suspended in solution. 10 μl of solution were taken from each well and mixed with equal 
parts Trypan blue. After at least a minute to allow for cell staining to occur, 10 μl of cell 
suspension/trypan stain solution were drawn off and dispensed over a hemocytometer for 
counting of viable cells to determine number of cells per treatment group.
Ames assay
Ames test kits were purchased from Environmental Bio-detection Products Inc. 
(EBPI), and the assay was carried out according to manufacturer’s instructions. The 
lyophilized bacterial culture was suspended in a liquid medium (Reagent G) 12 to 16 
hours prior to experimentation. Once suspended, the bacteria were placed in a shaking 
incubator at 37°C to replicate and grow overnight. The following day, experimental 
samples were prepared by diluting the Cr(VI) stock solution in sterile water to desired 
concentrations. Turbidity within the bacterial culture verified growth, and the OD600 
of the solution was measured by spectrophotometry. This OD (optical density) value 
was then used to bring the bacterial suspension to a desired concentration through 
a series of calculations (Appendix 1). Three samples of each treatment group were 
placed in a 24-well plate for the bacterial exposure period. Positive, negative, and 
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sterility controls were also included on the exposure plate. Added into each well was 
the treatment solution, exposure media, and the bacterial suspension, and the plate was 
incubated at 37°C for 100 minutes. During the incubation period, a reversion medium 
was prepared for the 96-well plates. After the bacteria had been incubated for 100 
minutes, the plate was removed and solution from each well was pipetted into a tube 
containing the premade reversion medium. Using loading boats and a multichannel 
pipette, each sample was pipetted into 48 wells of a 96-well plate. The 96-well plates 
were then placed in an incubator at 37°C for three days to allow for revertant bacteria 
to grow. After the three day incubation period, plates were scored by colorimetric 
determination with yellow and partial-yellow wells indicating genetic reversion.
Statistical analysis
The statistical analysis for both the cell proliferation data and the Ames assay data 
were done by a two-tailed t-test data with p-values < 0.05 determined to be statistically 
significant. The error bars depicted in the figures below show standard error of the mean.
RESULTS
To determine if antioxidants could prevent Cr(VI)-induced cytotoxicity, we first had 
to establish Cr(VI) toxicity without cotreatment with antioxidants. This also helped us 
determine a good concentration of Cr(VI) to use for cotreatment. HEK cells exposed 
to increasing concentrations of Cr(VI) displayed a marked reduction of cell viability. 
Figure 1 shows that Cr(VI) levels of 1000 ppb completely eradicated all cells in the 
treatment group. These data indicate not only the severity of Cr(VI) exposure but also 
provide a basis for a range of exposure doses and cellular susceptibility.  For this study, 
we chose to use 500 ppb Cr(VI) as an intermediate dose to elucidate the potency of the 
antioxidants vitamin C and EGCG.
Figure 1: Human embryonic kidney cells display reduced viability upon increasing exposure to Cr(VI). HEK 
cells were exposed to different doses of Cr(VI) ranging from 200 ppb to 1000 ppb. A negative dose response to Cr(VI) 
was observed.
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Next, we wanted to determine if the presence of vitamin C could prevent Cr(VI)-
induced cytotoxicity. To test for this, chromium concentrations were kept constant at 
500 ppb while varying concentrations of vitamin C were added as cotreatment. 50 ppm 
vitamin C was also run independently as a control group and yielded similar cell counts 
as the negative control, indicating a lack of cellular toxicity of vitamin C alone. Figure 
2 shows that 500 ppb Cr(VI) cotreated with as little as 5 ppm vitamin C more than 
doubled the cells per well from 500 ppb Cr(VI) alone. Furthermore, responses were 
observed in a dose dependent manner in wells cotreated with 10 and 25 ppm vitamin 
C. Importantly, there was no significant difference observed between 500 ppb Cr(VI) 
cotreated with 25 ppm vitamin C and the negative control.
Figure 2: The antioxidant vitamin C can prevent toxicity of Cr(VI). Human embryonic kidney cells were exposed 
to cotreated samples of 500 ppb Cr(VI) and differing concentrations of vitamin C. Likelihood of survival increased 
with the addition of vitamin C. Cr(VI) was completely mitigated by 25 ppm vitamin C.
These results were also replicated qualitatively upon a second cell line. Human intestinal 
epithelial cells were exposed to the same treatment groups as the above mentioned 
HEK cells. Due to difficulties in the cell counting procedure for this particular line 
of cells, representative pictures of treatment groups were taken to serve as alternative 
results to quantification. As shown in Figure 3, cotreatment with 25 ppm vitamin C 
markedly improved cytotoxic effects of 500 ppb Cv(VI). Together, these data suggest 
that Cr(VI) toxicity and the protective effect of vitamin C can be broadly applied across 
different cell types.
Not only were we interested in the protective potential of vitamin C, but antioxidants 
at large. To test this theory, we exposed HEK cells to solutions cotreated with 500 
ppb Cr(VI) and varying concentrations of EGCG to compare the efficacy of the two 
antioxidants (Figure 4). As in the case of vitamin C, EGCG demonstrated protective 
effects in a dose dependent manner starting at 7.5 ppb EGCG. However, unlike the 
complete protection from Cr(VI) toxicity that was observed with vitamin C at a lower 
dose, even the highest dose of EGCG was only able to protect approximately 60% of 
the HEK cells.
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Figure 3: Vitamin C protects human intestinal epithelial cells from Cr(VI)-induced cytotoxicity. Cells were ex-
posed to untreated cell media (panel A), as well as 500 ppb Cr(VI) (panel B) and 500 ppb Cr(VI) cotreated with 25 ppm 
vitamin C (panel C). Cotreatment mitigated nearly all observed effects of Cr(VI). This result was replicated on human 
embryonic kidney cells. These images were taken three days after exposure.
Figure 4: The antioxidant EGCG can prevent toxicity of Cr(VI). Human embryonic kidney cells were exposed to 
solutions of 500 ppb Cr(VI) cotreated with varying concentrations of EGCG. As EGCG concentrations increased, cell 
survival also increased.
We next wanted to test the protective potential of antioxidants against Cr(VI)-induced 
mutagenicity. To test this, bacteria were exposed to Cr(VI) as well as Cr(VI) cotreated 
with vitamin C in an Ames assay. Figure 5 shows that as Cr(VI) concentrations increased 
from 20 ppb to 2000 ppb, percent mutagenicity increased. Treatment groups of 20, 200, 
and 2000 ppb were significantly more mutagenic than the negative control. Cotreatment 
with 20 ppm vitamin C significantly reduced the mutagenicity of 200 ppb and 2000 ppb 
Cr(VI). Moreover, 20 ppm vitamin C was not found to be mutagenic itself.
DISCUSSION
After exposing human cell cultures to a range of Cr(VI) concentrations, we observed 
that increasing concentrations of Cr(VI) was associated with cell death of both HEK 
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Figure 5: Bacterial cells cotreated with vitamin C and Cr(VI) exhibit less mutagenesis than those without the 
antioxidant. Bacterial cultures exposed to solution containing higher levels of Cr(VI) were more likely to mutate DNA. 
Those exposed to high levels of Cr(VI) as well as vitamin C were less likely to mutate. * denotes p-value < 0.05 when 
compared to negative control, ** denotes p-value < 0.005 when compared to negative control, # denotes p-value < 0.05 
compared to that concentration of Cr(VI) alone. The positive control is a 12.5 ppb sodium azide solution.
and HIE cells (Figures 1 and 3). However, we found that the detrimental effects of 
Cr(VI) were mitigated by the addition of the antioxidants vitamin C or EGCG in a 
dose dependent manner (Figures 2 and 4). This evidence suggests that Cr(VI) is indeed 
cytotoxic via an oxidative mechanism, as the presence of an antioxidant reduced 
cytotoxicity.
Vitamin C was found to be a much more potent protective chemical than EGCG (Figures 
2 and 4). This could be due to the vast difference in the size of the two molecules, as 
ascorbic acid is much smaller than its counterpart. It’s unclear where the reduction of 
Cr(VI) into Cr(III) is occurring, whether inside the cell in the cytoplasm or outside the 
cell within the culture media, though it is probable that the majority is occurring in the 
media before the toxicant enters the cell. This is because the Cr(VI) was exposed to the 
antioxidant in solution hours before being dispensed over the cells. Indeed, metabolic 
clearance of Cr(VI) may likewise occur prior to cellular interaction. Roughly ten percent 
of inorganic Cr(VI) is absorbed through the intestinal tract (Yu, 2013). Excretion of 
absorbed chromium occurs primarily via urine. In humans, the kidney excretes about 
60% of an absorbed Cr(VI) dose in the form of Cr(III) within eight hours of ingestion. 
Approximately 10% of an absorbed dose is eliminated by biliary excretion, with 
smaller amounts excreted in hair, nails, milk, and sweat (Kiilunen & Kivisto, 1983). 
Therefore, a majority of the reduction interactions occurring between antioxidants and 
Cr(VI) likely take place before the two components enter the cell. However, while 
clearance from plasma is generally rapid (within hours), whereas elimination from 
tissues is slower, with a half-life of several days (ATSDR, 2012).
Data from the Ames assay further suggests that Cr(VI) is indeed mutagenic by way 
of oxidation. Though previous studies have shown that Cr(VI) is mutagenic (Petrilli 
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& Deflora, 1976), the novel cotreatment with antioxidants performed in this study 
show that chemical reduction decreases mutagenicity, indicating that the oxidative 
mechanism of Cr(VI) plays a critical role in mutagenesis. As bacterial strains were 
exposed to increasing concentrations of the toxicant, percent mutation increased as 
well. When exposed to solution cotreated with antioxidant, however, percent mutation 
was essentially nullified as levels were brought back down to those observed within the 
negative control group, regardless of the concentration of Cr(VI). That is, any group 
treated with vitamin C exhibited no significant change from the negative control, even 
at the highest concentration of Cr(VI) (2000 ppb).
Furthermore, neither antioxidant tested was found to be cytotoxic or mutagenic in-and-
of-itself. Thus, they may serve as a preventative protectant as pre-treatment within a 
drinking water supply. We cannot pre-treat the water with a level of protectant so high 
that it itself becomes a harmful contaminant. This concern is needless in this case as 
both vitamin C and EGCG showed great protective potential at levels at which they 
themselves were harmless.
It appears that Cr(VI) is more mutagenic towards bacterial DNA at lower concentrations 
(20 ppb) than it is cytotoxic towards mammalian cells (200 ppb). This result may 
suggest two things. One reason for this discrepancy may be that bacterial cells are 
more sensitive to Cr(VI); this is probably a result of the vast differences between 
prokaryotic and eukaryotic cells. Eukaryotes have several other cellular components 
that Cr(VI) may interact with before reaching the DNA within the nucleus. The 
second conclusion may be that mutagenicity is also occurring in the mammalian cells 
at concentrations similar to that in the bacteria, but that the mutations occurring are 
nonlethal or nonharmful. This would be a reasonable assumption, as a mammalian 
eukaryotic cell has far more DNA than a prokaryotic bacterium (Alberts et al., 2015). 
Additionally, a prokaryotic genome has fewer regions of noncoding DNA (20%) than 
that of a eukaryote (98%) (Alberts et al., 2015). Therefore, there is a greater likelihood 
that a mutagen would affect a critical region in the bacterial genome, while eukaryotic 
cells are afforded a degree of insulation by vast noncoding stretches of DNA that can 
absorb mutagens such as Cr(VI). In either case, this merits further research into Cr(VI) 
mutagenicity in a mammalian cell line.
This study focused only on the cotreatment of antioxidants with Cr(VI) as opposed to 
pre-treatment or post-treatment. Specifically, both bacterial cells in the Ames test and 
human cells in the cell proliferation assay were exposed to both the toxicant and the 
protectant simultaneously. In both assays, the cotreated solution was prepared one to 
ten hours before cell exposure. Because of this, the chemical interaction taking place 
between the two compounds likely occurs in solution. An interesting continuation of 
this study would be examining the differences between a cotreatment with antioxidant 
(as performed in this study) and a pre or post-treatment with antioxidant. This would 
provide information as to whether antioxidants could protect against impending Cr(VI) 
exposure or help cells recover from prior Cr(VI) exposure. These assays would also 
shed more light as to where the majority of the chemical reduction of the chromium is 
occurring, either in solution or within the cells themselves.
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These data come at a time when hundreds of millions of Americans are exposed to 
hexavalent chromium in their daily water supply (Andrews & Walker, 2016). The 
protective potential of antioxidants is promising, and applications of this research are 
numerous. For example, just as many European countries began adding fluoride to 
public water supplies in the early 1990s to prevent dental caries, antioxidants may be 
useful additions to water supplies known to have higher concentrations of Cr(VI) or 
areas at higher risk of Cr(VI) contamination. Moreover, these findings suggest that 
antioxidants as reducing agents may also be applied in mitigation of other harmful 
oxidizers. Though continued study is merited, this information further validates the 
protective potential of antioxidants and will be helpful for government agencies and 
organizations in determining safe levels of water chromium.
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APPENDIX
X = OD600 measurement for overnight bacteria, Y = Working concentration
(For this specific strain, TA100, the working concentration is 0.05 at OD600),
Final volume = 6 mL.
Volume of overnight bacteria (mL) required for dilution = Y/X  × Final volume
Example: TA100 was grown overnight and recorded an OD600 = 0.65
Volume of TA100 required for dilution =  (0.05)/(0.65) × 6 = 0.46 mL
Therefore, 0.46 mL of overnight bacterial solution will be added to 5.54 ml
of Reagent N to bring the final volume to 6 mL.
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